(Incorporated in Delaware) We supply specialty chemicals to manufacturers of pharmaceutical, electronic, industrial and personal care products, as well as to research organizations. We obtain our products in China through a network of third-party manufacturers. Sulfonyl chemicals, phosphorus chemicals and other specialty intermediates make up part of our product line. Note: Net income and revenue […]

(Incorporated in the Cayman Islands) We are a newly organized blank check company. We intend to target the manufacturing sector. Our focus will include, but not be limited to, aerospace and defense, industrial technology and critical supply chains. CEO Michel Tamer is the managing director of M&A at NorthStrive Companies. CFO James Dawson is the […]

(Incorporated in the Cayman Islands) We are a newly organized blank check company. We anticipate focusing primarily on the commercial finance and consumer finance sectors as well as ancillary verticals such as financial technology (FinTech). CEO and Chairman Steven K. Hudson is  the former CEO of ECN Capital Corp., an originator and manager of prime […]

(Incorporated in the Cayman Islands) Note: This SPAC is offering only stock. This is NOT a unit offering. A typical SPAC IPO is a unit offering that usually includes a warrant or a right with a share of stock in each unit. We are a newly organized blank check company concentrating on healthcare in Asia. […]

(Incorporated in the Cayman Islands) We are a newly organized blank check company. We intend to search for an acquisition target in the technology sector. We expect to focus our search on finding a technology growth company that has artificial intelligence (AI) tailwinds where we believe our management team and founders’ expertise will provide us […]

(Incorporated in the Cayman Islands) We are a newly organized blank check company. Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region. Because of our significant ties to China, we may pursue opportunities in China (including Hong Kong and Macau). (Note: Southern Cross Acquisition II Corp. […]

(Incorporated in Delaware) We are a Phase 2 biotech focused on developing NanO2, an IV-administered oxygen therapy to treat hypoxia. NanO2 is based on dodecafluoropentane.  The focus of our clinical research and development to date has been on the administration of NanO2 to treat acute ischemic stroke and GBM (glioblastoma). We have additional programs in earlier-stage […]

(Incorporated in Delaware) We are a Phase 2 clinical biotech developing drugs to treat endocrine and metabolic disorders. Our focus is on post-bariatric hypoglycemia (PBH) and gastroparesis. Our lead product candidate, mizagliflozin, is an oral drug candidate (a pill) in development in a Phase 2B study to treat post-bariatric hypoglycemia. Mizaglifozin is a minimally absorbed […]

(Incorporated in Delaware) We are a clinical biopharmaceutical company developing non-opioid oral therapies for acute and chronic pain. We are ready for Phase 3. We are committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Pain represents one of the largest and […]

(Incorporated in Delaware) We are a Phase 2-ready clinical biopharma company focused on developing small-molecule medicines to treat cancer. Our leading drug candidate, BH-30643, is in SOLARA, our global Phase 1/2 trial for EGFR-mutant non-small cell lung cancer (NSCLC). There is is a fragmentation of care in EGFR-mutant NSCLC because no drug is effective across […]